No Shire? No problem for AbbVie. At least, for now.
Mergers and acquisitions have been non-stop this year, with lots of deals done, and some doozies that were unable to cross the finish line. Here we look at what's happened in the first half of the year; we will round out the entire year's activity in another report early next year.
The top 10 deals in the first half of 2014 totaled nearly $90 billion in value, with Actavis' $25 billion deal for Forest topping the list. According to EvaluatePharma's estimates, the deals worth about $50 billion surfaced in just the second quarter, making it the biggest quarter since at least 2007 if megamergers are factored out.
Sovaldi is pricey, but if you want to talk about really pricey, then look at the 10 most expensive drugs. The least of those, Celgene's Revlimid, ran $128,666 last year, the numbers ninjas at EvaluatePharma determined. The most expensive, Soliris, costs nearly $537,000.
Of course, debate about the appropriate price for drugs is ongoing. It costs a lot of money to discover and develop drugs, including the money that gets sunk into candidates that don't succeed. And because of the way the U.S. market works, it will have the highest prices that the market will bear.
FiercePharma is now available on iPhone and iPad!
This is the best FiercePharma reading experience we've ever created. Swipe right-to-left within articles to quickly scan the latest news. Get breaking news alerts sent to your mobile device so you're the first to know when a major story unfolds. Download it today; the app is an essential complement to our e-mail newsletter and website.
Have something to say? Join the conversation at
FiercePharma's LinkedIn group.
POPULAR COMMENT THREADS
About 240 workers at a Boehringer Ingelheim complex in Virginia will have something special to celebrate this Thanksgiving: the prospect of keeping their jobs. Just weeks ahead of closing the facility and laying off all its workers, Boehringer has found a Chinese buyer that intends to add to the headcount there.
Cipla petitions India to revoke Novartis respiratory drug patents, launches low-cost version of drug
Amid growing discontent from Big Pharma companies over India's patent-busting policies, generics maker Cipla is petitioning the country's government to revoke 5 patents for Novartis' respiratory drug Indacterol and is launching a low-cost version of the product to boost local access.
Express Scripts--which has made its feelings well known when it comes to the high cost of Gilead's next-gen hepatitis C drugs--says it may quickly change its preferred drug formulary to favor a anticipated challenger from the Illinois company, Reuters reports, provided it's clinically equivalent--and less expensive, of course.
Boehringer Ingelheim has completed a trifecta of approvals for its blood thinner Pradaxa for deep vein thrombosis and pulmonary embolism. The U.K. cost watchdog NICE has now given it a thumbs up after the FDA and the European regulators did the same thing this year.
Impax Laboratories, which has struggled for several years to get its Parkinson's drug Rytary to market, is moving away from early-stage research and has cut its R&D staff by 42 jobs, a 25% reduction to save money.
Bernstein analyst Tim Anderson figures Sanofi would do well to look outside the company for its new CEO, like AstraZeneca did with its new-ish chief, Pascal Soriot. Well, Sanofi had a more literal view: The French drugmaker has contacted Soriot himself.
From Our Sister Sites
U.K. researchers have hit upon a drug combination that appears to combat lung cancer by triggering self-destruction in tumor cells.
Amid efforts to counter the deadly Ebola outbreak, researchers and companies are homing in on rapid mobile tests as a more effective way to prevent the disease's spread.